


Pharmaceuticals & Biotechnology | Small Cap
Lincoln Pharmaceuticals demonstrates strong financial health, particularly in solvency and growth. The company efficiently manages its debts and shows good growth in revenue, operating profit, and assets. Profitability is also a notable strength, with solid returns on capital, equity, and assets, along with healthy margins. However, there are areas needing attention. The company's efficiency ratios are weak, indicating challenges in managing assets and inventory. Financial ratios also show some concerns, particularly regarding capital expenditures and earnings per share. While liquidity is reasonably managed, there is room for improvement. Overall, Lincoln Pharmaceuticals presents a mixed picture, with significant strengths offset by identifiable weaknesses in operational efficiency and financial management.
Lincoln Pharmaceuticals demonstrates strong financial health, particularly in solvency and growth. The company efficiently manages its debts and shows good growth in revenue, operating profit, and assets. Profitability is also a notable strength, with solid returns on capital, equity, and assets, along with healthy margins. However, there are areas needing attention. The company's efficiency ratios are weak, indicating challenges in managing assets and inventory. Financial ratios also show some concerns, particularly regarding capital expenditures and earnings per share. While liquidity is reasonably managed, there is room for improvement. Overall, Lincoln Pharmaceuticals presents a mixed picture, with significant strengths offset by identifiable weaknesses in operational efficiency and financial management.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
13.81
Industry Median
33.01
Small Cap Median
31.82
P/E RATIO
13.81
P/B RATIO
1.60
Industry Median
3.66
Small Cap Median
3.57
P/S RATIO
1.81
Industry Median
2.26
Small Cap Median
2.09
Others
PEG RATIO
0.00
EV/EBITDA RATIO
9.00
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹606.2 as on Aug 6, 2026.
The company exhibits strong growth across various metrics, including revenue, operating profit, earnings per share, assets, and net income. This indicates a healthy expansion and effective management strategies. The consistent growth rates suggest the company is well-positioned for future success. Weighted average calculation method was used to arrive at the score.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 11.32 | 8.05 | 13.92 | 7.23 | 7.7 |
| Operating Profit Growth Rate | 10.34 | -6.25 | 11.11 | 2 | -3.92 |
| Earnings Per Share (EPS) Growth | 11.28 | 5.11 | 27.97 | -11.74 | 6.74 |
| Asset Growth Rate | 18.14 | 9.93 | 19.25 | 13.86 | 11.67 |
| Net Income Growth Rate | 11.29 | 5.8 | 27.4 | -11.83 | 7.32 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 37.02 | Overvalued | 58.00 | 6.54 | 43.00 |
| 2 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 3 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.81 | Neutral | 98.00 | 43.88 | 88.00 |
| 4 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 5 | NGL Fine Chem Ltd | 6.98 | 44.01 | Overvalued | 73.00 | 67.39 | 48.00 |
| 6 | Syncom Formulations (India) Ltd | 6.92 | 16.27 | Undervalued | 77.00 | 0.81 | 76.00 |
| 7 | Sakar Healthcare Ltd | 6.89 | 67.13 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 8 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 9 | Kopran Ltd | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 10 | SMS Lifesciences India Ltd | 6.59 | 21.63 | Undervalued | 45.00 | 58.80 | 19.00 |
| 11 | Hester Biosciences Ltd | 6.54 | 37.59 | Neutral | 87.00 | 61.24 | 57.00 |
| 12 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 13 | Medicamen Biotech Ltd | 5.73 | 33.43 | Neutral | 20.00 | 6.94 | 10.00 |
| 14 | Albert David Ltd | 5.63 | -279.90 | Neutral | 5.00 | -2.62 | -1.00 |
| 15 | Remus Pharmaceuticals Ltd | 5.31 | 25.82 | Neutral | 57.00 | 20.97 | 46.00 |
| 16 | Ind-Swift Laboratories Ltd | 4.95 | 47.48 | Neutral | 45.00 | 4.89 | 41.00 |
| 17 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 18 | Wanbury Ltd | 4.65 | 29.43 | Neutral | 88.00 | 18.93 | 43.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Concall Report⬤23rd Feb 26
Q3 FY26 Earnings Conference Call
BULLISH SENTIMENT